DeCode Launches Pharmacogenomics and Cancer Subsidiaries | GenomeWeb

NEW YORK, Nov 29 –DeCode Genetics, in an effort to transform its raw population genomics data into revenue-generating products, has launched two new subsidiaries: Encode for pharmacogenic studies and DeCode Cancer for developing cancer diagnostic and therapeutic products, the company said Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.